Related Experiment Video
Updated: Oct 11, 2025
08:47
Microdialysis of Excitatory Amino Acids During EEG Recordings in Freely Moving Rats
Published on: November 8, 2018
11.6K
Topiramate-Related Hyperammonemia
Kelly Moore1, Deepali Dixit2,3, Mary Wagner2,3
1Hospital of Special Surgery, New York, NY, USA.
Summary
This case highlights topiramate-related hyperammonemia, a serious condition exacerbated by valproic acid. Discontinuing topiramate and tapering valproic acid normalized ammonia levels, confirming a drug interaction.
Area of Science:
- Neurology
- Clinical Pharmacology
Background:
- Valproic acid is known to cause hyperammonemic encephalopathy.
- The interaction between topiramate and valproic acid leading to hyperammonemia is documented but requires further investigation.
Purpose of the Study:
- To report a case of hyperammonemia resulting from the interaction between topiramate and valproic acid.
- To emphasize the pharmacodynamic interaction between these two drugs.
Main Methods:
- A patient case report detailing the onset and resolution of hyperammonemia.
- Monitoring of ammonia levels following administration and discontinuation/tapering of topiramate and valproic acid.
Main Results:
- The patient developed hyperammonemia after receiving valproic acid while already on topiramate.
- Elevated ammonia levels worsened with increased valproic acid dosing frequency.
- Ammonia levels normalized upon discontinuation of topiramate and tapering of valproic acid.
Conclusions:
- This case supports the association of topiramate with hyperammonemia.
- The co-administration of valproic acid can pharmacodynamically interact with topiramate, leading to hyperammonemia.
More Related Videos
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
584
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
584
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
788
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
788
01:20Antiepileptic Drugs: Potassium Channel Activators
340
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
340
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
514
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
514
01:20Inborn Errors of Metabolism
301
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
301
01:23Urea Cycle
46.8K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
46.8K